Dose-Limiting Pulmonary Toxicity in a Phase 1/2 Study of Radiation and Chemotherapy with Ipilimumab Followed by Nivolumab for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer
Casey Liveringhouse(Moffitt Cancer Center), Bradford A. Perez(Moffitt Cancer Center), Tawee Tanvetyanon(Moffitt Cancer Center), Michael Shafique(Moffitt Cancer Center), Scott Antonia(Moffitt Cancer Center), Kujtim Latifi(Moffitt Cancer Center), Andreas Saltos(Moffitt Cancer Center), Michael J. Schell(University of Bonn), José R. Conejo-García(Duke University), Ashley Weiner(University of North Carolina Hospitals), Eric B. Haura(Moffitt Cancer Center), Ben Creelan(Moffitt Cancer Center), Jeffrey Clarke(Duke Medical Center), Nghi B. Lam(Moffitt Cancer Center), Alberto Chiappori(Moffitt Cancer Center), Amalin G. Asous(Moffitt Cancer Center), Trevor Rose(Moffitt Cancer Center), Jiannong Li(Moffitt Cancer Center), J.J. Caudell(Moffitt Cancer Center), Thomas J. Dilling(Moffitt Cancer Center), Sungjune Kim(Jacksonville College), Stephen A. Rosenberg(Moffitt Cancer Center), Chris R. Kelsey(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Gretchen V. MacMillan(Moffitt Cancer Center), Jhanelle E. Gray(Moffitt Cancer Center)
International Journal of Radiation Oncology*Biology*Physics
January 17, 2023
Cited by 18
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
|The Lancet Oncology|2016|1.3k
Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2015|1.2k
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021
|Journal of the National Comprehensive Cancer Network|2021|1k